Diagnosis and treatment of common sexually transmitted diseases in women

Laboratory investigation: Sexually transmitted diseases

Sexually transmitted diseases are among the most common infectious diseases and pose a major public health concern globally. Unfortunately, such diseases are often asymptomatic, and are left untreated for long periods of time-resulting in significant health care costs and morbidity rates. In recent years, the advancement in diagnostic testing has been tremendous, especially at the molecular level of disease. In the paper to follow, we will attempt to examine diagnostic techniques traditionally used (microscopic examination and culture) to identify STDs and compare them to newly introduced techniques (including DNA amplification and hybridization) that provide higher sensitivity and specificity, as well as shorter result reporting time.

Chlamydia and gonorrhoea in pregnancy: effectiveness of diagnosis and treatment in Botswana

BACKGROUND

Millions of patients are prescribed drugs for sexually transmitted infections (STIs) in developing countries each year, yet the treatment effect of these prescriptions is largely unknown.

OBJECTIVES

To determine if the prescribing of erythromycin and ceftriaxone to pregnant women with STI symptoms leads to a reduction in the prevalence among these women of chlamydia and gonorrhoea, respectively.

METHODS

We compared the prevalence of chlamydia among 116 pregnant women who had been prescribed erythromycin for a history of STI symptoms in their current pregnancy with the prevalence in a control group of 557 pregnant women who had not been prescribed this drug. Similarly we compared the prevalence of gonorrhoea among 110 pregnant women who had and 561 women who had not been prescribed ceftriaxone.

RESULTS

There was no significant difference in the prevalence of chlamydia among the women who had and the women who had not been prescribed erythromycin four times daily for 10 days (7% v 8%). Contrarily, none of the women who had been prescribed a single dose of ceftriaxone had gonorrhoea, whereas 4% of the women who had not had this drug prescribed did have gonorrhoea.

CONCLUSIONS

The prescribing of erythromycin seems to have had a limited effect on chlamydia in this population, whereas the prescribing of ceftriaxone led to the curing of gonorrhoea. Ceftriaxone is provided as a single dose injection at the point of care, and the differential effectiveness between the two drugs may reflect low compliance with the complex erythromycin regimen. Interventions to increase compliance could improve cure rates. The use of a simpler drug regimen should be considered when low compliance is likely.